New Joint FDA/NCI Cancer Program

Publication
Article
OncologyONCOLOGY Vol 15 No 9
Volume 15
Issue 9

The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) inaugurated a new program in July that

The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) inaugurated a new program in July that willintegrate the study of all proteins in living cells (or proteomics) with patientcare. 

"This new approach to treatment holds the potential to revolutionizecancer detection and care," said Health and Human Services Secretary TommyG. Thompson. The agency collaboration is being led by Emanuel Petricoin, PhD, ofthe FDA’s Center for Biologics Evaluation and Research, and Lance Liotta, MD,PhD, of NCI’s Center for Cancer Research. 

The Clinical Proteomics Program willbe funded for 3 years at $1.1 million per year. Drs. Petricoin and Liotta haveidentified more than 130 proteins in cancers of the breast, ovary, prostate, andesophagus that change in amount as the cells in these tissues grow abnormally,which may provide new means of diagnosing and treating cancers earlier. The NCIhas recently begun clinical trials using proteomics to help make decisions aboutthe course of a patient’s experimental treatment.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content